MHRA Approves First Oral Treatment for Hereditary Angioedema Attacks

MHRA approves first oral treatment for hereditary angioedema attacks

Sebetralstat offers injection-free relief for patients aged 12 and over

KalVista Secures FDA Approval for First-Ever Oral On-Demand HAE Treatment – Patient Worthy

KalVista Pharmaceuticals has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of its new oral therapy for hereditary angioedema (HAE), marking a breakthrough for patients who have long relied on injectable treatments. The FDA endorsement, as reported by pharmaphorum.com, makes this the first oral, on-demand medication available for treating acute […]